Xtant Medical Stock Price, News & Analysis

Xtant Medical Holdings (NYSE American: XTNT) has entered into a definitive agreement for a private placement to raise approximately $20 million. The agreement includes the sale of 8,888,890 common shares and warrants to purchase 6,666,668 common shares, priced at $2.25 each. Proceeds will be used for working capital and corporate purposes. The placement is expected to close around February 24, 2021, pending regulatory approvals. A.G.P./Alliance Global Partners is the sole placement agent.

Xtant Medical Holdings, Inc. (NYSE American: XTNT) will release its financial results for the fourth quarter and full year ended December 31, 2020, on February 24, 2021, before market open. The results will be discussed in a conference call at 9:00 AM ET the same day, led by CEO Sean Browne and CFO Greg Jensen. Investors can join the call at 877-407-6184 or through international dial-in at 201-389-0877. A replay will be available on the company's website post-call. Xtant Medical specializes in surgical solutions for spinal disorders.

Xtant Medical Holdings, Inc. (NYSE American: XTNT) announced that the subscription period for its rights offering expired on December 4, 2020. The company expects to issue approximately 711,143 shares at a subscription price of $1.07, generating gross proceeds of around $761,000. This is based on preliminary results from EQ Shareowner Services. The offering's final results await verification. The company’s SEC registration statement was effective as of November 3, 2020. Interested parties can find more details on the SEC's website.

Xtant Medical Holdings reported third-quarter 2020 revenues of $14.0 million, a 33% increase from Q2 2020 but a 10.9% decline year-over-year. Operating expenses fell to $8.5 million from $11.1 million in Q3 2019, aiding an income from operations of $0.8 million. The net loss was $1.4 million, improved from a loss of $1.9 million in Q3 2019. Adjusted EBITDA rose to $1.6 million, up from $0.6 million a year ago. The company also announced a proposed rights offering of up to $15 million of common stock.

Xtant Medical Holdings (XTNT) has announced a rights offering of up to $15 million in common stock, with a record date set for November 5, 2020. Each stockholder will receive subscription rights enabling them to purchase shares at a price of $1.07 per share. The offering begins on November 5, 2020, pending registration approval, and concludes on December 4, 2020, with over-subscription privileges available. The company intends to distribute subscription materials by November 6, 2020. This offering aims to bolster Xtant's funding for developing surgical solutions for spinal disorders.

Xtant Medical Holdings (XTNT) is set to release its third quarter financial results for the period ending September 30, 2020, on October 29, 2020, before market open. A conference call featuring CEO Sean Browne and CFO Greg Jensen will take place on the same day at 9 AM ET to discuss the results. The call can be accessed via dial-in or webcast. Xtant Medical specializes in surgical solutions for spinal disorders, with a focus on orthobiologics and spinal implant systems.

Xtant Medical Holdings, Inc. (NYSE American: XTNT) has regained compliance with NYSE American listing standards, specifically maintaining stockholders' equity of at least $6 million after facing losses. This compliance was achieved through a debt restructuring transaction, involving the issuance of approximately 57.8 million shares at $1.07 each, in exchange for $40.8 million in loans and $21.1 million in PIK Interest. The compliance marker will be removed, positively impacting XTNT's standing on the NYSE American.

Xtant Medical Holdings (NYSE American: XTNT) announced the completion of a debt restructuring aimed at enhancing its capital structure. This restructuring reduces its total indebtedness to under $16 million and lowers its cost of debt. Approximately 57.8 million shares were issued to lenders, converting about $40.8 million in loans into equity at an exchange price of $1.07 per share. Following the restructuring, OrbiMed funds own approximately 94.5% of XTNT's stock. Additionally, Xtant plans a rights offering for existing shareholders to purchase stock at the same price.

Xtant Medical Holdings, Inc. (NYSE American: XTNT) announced a Restructuring and Exchange Agreement aimed at improving its capital structure. This agreement involves converting approximately $40.8 million in loans into about 57.8 million shares of common stock at an exchange price of $1.07 per share. Post-restructuring, Xtant will have less than $17 million in debt. The agreement also includes launching a rights offering for stockholders to purchase common stock valued at $15 million. The restructuring aims to facilitate future investments and compliance with NYSE American listing standards.